Discounted Cash Flow Rating

Neutral

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Upgrade To View Simple Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Exponential Moving Average Rating

Upgrade

Upgrade To Get Access

Upgrade To View Relative Strength Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Standard Deviation Rating

Upgrade

Upgrade To Get Access

Upgrade To View Williams %R Rating

Upgrade

Upgrade To Get Access

Upgrade To View Average Directional Index Rating

Upgrade

Upgrade To Get Access

Upgrade To View Insider Trading Rating

Upgrade

Upgrade To Get Access

Wall Street Data Solutions Rating

Neutral

B

InflaRx N.V. Common Stock (IFRX)

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

11/08/2017

Market Cap

78,903,622

Shares Outstanding

58,880,000

Weighted SO

58,883,272

Total Employees

N/A

Upcoming Earnings

08/08/2024

Similar Tickers

GBIO --.--%

KRON --.--%

ERAS --.--%

CCCC --.--%

EWTX --.--%

KZR --.--%

FULC --.--%

PASG --.--%

ABOS --.--%

Beta

1.5830

Last Div

0.0000

Range

1.14-4.3

Chg

-0.0200

Avg Vol

116100

Mkt Cap

78903622

Exch

NASDAQ

Country

DE

Phone

49 3641 508 180

DCF Diff

1.1019

DCF

0.2381

Div Yield

0.0000

P/S

678.1686

EV Multiple

-1.0690

P/FV

0.8717

Div Yield %

0.0000

P/E

-1.5377

PEG

0.0625

Payout

0.0000

Current Ratio

8.9140

Quick Ratio

7.9723

Cash Ratio

1.8699

DSO

6218.2107

DIO

3028.7969

Op Cycle

9247.0077

DPO

2683.5468

CCC

6563.4609

Gross Margin

-10.0053

Op Margin

-492.0249

Pretax Margin

-441.0271

Net Margin

-441.0271

Eff Tax Rate

-0.0001

ROA

-0.5006

ROE

-0.4687

ROCE

-0.6276

NI/EBT

1.0000

EBT/EBIT

0.8964

EBIT/Rev

-492.0249

Debt Ratio

0.0107

D/E

0.0122

LT Debt/Cap

0.0073

Total Debt/Cap

0.0120

Int Coverage

-1751.6772

CF/Debt

-42.6212

Equity Multi

1.1324

Rec Turnover

0.0587

Pay Turnover

0.1360

Inv Turnover

0.1205

FA Turnover

0.0864

Asset Turnover

0.0011

OCF/Share

-0.7230

FCF/Share

-0.7240

Cash/Share

1.2743

OCF/Sales

-402.9054

FCF/OCF

1.0014

CF Coverage

-42.6212

ST Coverage

-107.0494

CapEx Coverage

-733.6547

Div&CapEx Cov

-733.6547

P/BV

0.8717

P/B

0.8717

P/S

678.1686

P/E

-1.5377

P/FCF

-1.6809

P/OCF

-1.6832

P/CF

-1.6832

PEG

0.0625

P/S

678.1686

EV Multiple

-1.0690

P/FV

0.8717

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. May 28, 05:30 InflaRx Announces Outcome of Interim Analysis for Vilobelimab Phase 3 Trial in Pyoderma Gangrenosum GlobeNewswire Inc. Feb 14, 02:45 InflaRx Announces Pricing of $30 Million Public Offering of Ordinary Shares and Pre-Funded Warrants GlobeNewswire Inc. Nov 06, 07:30 InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma Gangrenosum GlobeNewswire Inc. Nov 01, 07:30 InflaRx Reports Third Quarter 2023 Financial Results and Provides Business Update

Revenue Product Segmentation